Search

Your search keyword '"Compagno, Mirko"' showing total 32 results
Start Over Author "Compagno, Mirko"
32 results on '"Compagno, Mirko"'

3. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases

Author

Goletti, Delia, Navarra, Assunta, Petruccioli, Elisa, Cimaglia, Claudia, Compagno, Mirko, Cuzzi, Gilda, De Carli, Gabriella, Fondaco, Laura, Franzetti, Fabio, Giannetti, Alberto, Gori, Andrea, Lapadula, Giuseppe, Lichtner, Miriam, Mastroianni, Claudio M., Mazzotta, Valentina, Orchi, Nicoletta, Pavone, Paolo, Piacentini, Daniela, Pirriatore, Veronica, Pontali, Emanuele, Sarmati, Loredana, Spolti, Anna, Tacconelli, Evelina, Galli, Massimo, Antinori, Andrea, Calcagno, Andrea, and Girardi, Enrico

Published
2020
Full Text
View/download PDF

4. Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Acinetobacter baumannii Infections

Author

Campogiani, Laura, primary, Crea, Angela Maria Antonia, additional, Minardi, Maria Letizia, additional, Ansaldo, Lorenzo, additional, Coppola, Luigi, additional, Compagno, Mirko, additional, Vitale, Pietro, additional, Spalliera, Ilaria, additional, Malagnino, Vincenzo, additional, Teti, Elisabetta, additional, D’agostini, C, additional, Pennacchiotti, Chiara, additional, Abate, Davide Natale, additional, Celeste, Maria Grazia, additional, Andreoni, Massimo, additional, Iannetta, Marco, additional, and Sarmati, Loredana, additional

Published
2023
Full Text
View/download PDF

6. Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection.

Author

Ferrari, Ludovica, Ruggiero, Alessandra, Stefani, Chiara, Benedetti, Livia, Piermatteo, Lorenzo, Andreassi, Eleonora, Caldara, Federica, Zace, Drieda, Pagliari, Matteo, Ceccherini-Silberstein, Francesca, Jones, Christopher, Iannetta, Marco, Geretti, Anna Maria, Ansaldo, Lorenzo, Bertoli, Ada, Bonfante, Francesco, Braccialarghe, Neva, Checchi, Davide, Compagno, Mirko, and De Simone, Giuseppe

Subjects
HIV infections, SARS-CoV-2, IMMUNOASSAY, VACCINATION, CHEMILUMINESCENCE immunoassay, ADULTS
Abstract

Accessible SARS-CoV-2-specific immunoassays may inform clinical management in people with HIV, particularly in case of persisting immunodysfunction. We prospectively studied their application in vaccine recipients with HIV, purposely including participants with a history of advanced HIV infection. Participants received one (n = 250), two (n = 249) or three (n = 42) doses of the BNT162b2 vaccine. Adverse events were documented through questionnaires. Sample collection occurred pre-vaccination and a median of 4 weeks post-second dose and 14 weeks post-third dose. Anti-spike and anti-nucleocapsid antibodies were measured with the Roche Elecsys chemiluminescence immunoassays. Neutralising activity was evaluated using the GenScript cPass surrogate virus neutralisation test, following validation against a Plaque Reduction Neutralization Test. T-cell reactivity was assessed with the Roche SARS-CoV-2 IFNγ release assay. Primary vaccination (2 doses) was well tolerated and elicited measurable anti-spike antibodies in 202/206 (98.0%) participants. Anti-spike titres varied widely, influenced by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as independent predictors. A third vaccine dose significantly boosted anti-spike and neutralising responses, reducing variability. Anti-spike titres > 15 U/mL correlated with neutralising activity in 136/144 paired samples (94.4%). Three participants with detectable anti-S antibodies did not develop cPass neutralising responses post-third dose, yet displayed SARS-CoV-2 specific IFNγ responses. SARS-CoV-2 vaccination is well-tolerated and immunogenic in adults with HIV, with responses improving post-third dose. Anti-spike antibodies serve as a reliable indicator of neutralising activity. Discordances between anti-spike and neutralising responses were accompanied by detectable IFN-γ responses, underlining the complexity of the immune response in this population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study

Author

Campogiani, Laura, primary, Vitale, Pietro, additional, Lodi, Alessandra, additional, Imeneo, Alessandra, additional, Fontana, Carla, additional, D’Agostini, Cartesio, additional, Compagno, Mirko, additional, Coppola, Luigi, additional, Spalliera, Ilaria, additional, Malagnino, Vincenzo, additional, Teti, Elisabetta, additional, Iannetta, Marco, additional, Andreoni, Massimo, additional, and Sarmati, Loredana, additional

Published
2023
Full Text
View/download PDF

9. Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence

Author

Rindi, Lorenzo Vittorio, Zace, Drieda, Compagno, Mirko, Colagrossi, Luna, Santoro, Maria Mercedes, Andreoni, Massimo, Perno, Carlo Federico, and Sarmati, Loredana

Abstract

ObjectiveWhile antiretroviral therapy (ART) is highly effective, detection of low levels of HIV-1 RNA in plasma is common in treated individuals. Given the uncertainties on the topic, we convened a panel of experts to consider different clinical scenarios, producing a Delphi consensus to help guide clinical practice.MethodsA panel of 17 experts in infectious diseases, virology and immunology rated 32 statements related to four distinct scenarios: (1) low-level viremia during stable (≥6 months) first-line ART (≥2 consecutive HIV-1 RNA measurements 50–500 copies/mL); (2) a viral blip during otherwise suppressive ART (a HIV-1 RNA measurement 50–1000 copies/mL with adjacent measurements <50 copies/mL); (3) low-level viral rebound during previously suppressive ART (≥2 consecutive HIV-1 RNA measurements 50–500 copies/mL); (4) residual viremia during suppressive ART (persistent HIV-1 RNA quantification below 50 copies/mL). A systematic review, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement, informed the 32 statements. The Delphi procedure was modified to include two voting rounds separated by a moderated group discussion. Grading of Recommendations, Assessment, Development, and Evaluations-based recommendations were developed.ResultsOverall, 18/32 statements (56.2%) achieved a strong consensus, 3/32 (9.4%) achieved a moderate consensus and 11/32 (34.4%) did not achieve a consensus. Across the four scenarios, the panel unanimously emphasised the importance of implementing specific interventions prior to considering therapy changes, including assessing adherence, testing for genotypic drug resistance and scheduling more frequent follow-up visits. Strategies indicated in selected circumstances included therapeutic drug monitoring, quantifying total HIV-1 DNA and evaluating concomitant chronic infections.ConclusionsWhile acknowledging the many uncertainties about source, significance and optimal management of low-level viremia during ART, the findings provide insights to help harmonise clinical practice. There is a need for well-designed randomised studies assessing different interventions to manage low-level viremia and future research regarding its definition.

Published
2024
Full Text
View/download PDF

10. Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience

Author

Campogiani, Laura, primary, Iannetta, Marco, additional, Di Lorenzo, Andrea, additional, Zordan, Marta, additional, Pace, Pier Giorgio, additional, Coppola, Luigi, additional, Compagno, Mirko, additional, Malagnino, Vincenzo, additional, Teti, Elisabetta, additional, Andreoni, Massimo, additional, and Sarmati, Loredana, additional

Published
2023
Full Text
View/download PDF

11. Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort

Author

Malagnino, Vincenzo, primary, Salpini, Romina, additional, Teti, Elisabetta, additional, Compagno, Mirko, additional, Ferrari, Ludovica, additional, Mulas, Tiziana, additional, Svicher, Valentina, additional, Zordan, Marta, additional, Basso, Monica, additional, Battagin, Giuliana, additional, Panese, Sandro, additional, Rossi, Maria Cristina, additional, Scaggiante, Renzo, additional, Zago, Daniela, additional, Iannetta, Marco, additional, Parisi, Saverio Giuseppe, additional, Andreoni, Massimo, additional, and Sarmati, Loredana, additional

Published
2023
Full Text
View/download PDF

12. Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Author

Cusato, Jessica, primary, Borghetti, Alberto, additional, Teti, Elisabetta, additional, Milesi, Maurizio, additional, Tettoni, Maria Cristina, additional, Bonora, Stefano, additional, Trunfio, Mattia, additional, D’Avolio, Antonio, additional, Compagno, Mirko, additional, Di Giambenedetto, Simona, additional, Di Perri, Giovanni, additional, and Calcagno, Andrea, additional

Published
2022
Full Text
View/download PDF

14. 1045. Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration T-lymphocyte Counts and Interferon-gamma Production

Author

Imeneo, Alessandra, primary, Alessio, Grazia, additional, Lorenzo, Andrea Di, additional, Campogiani, Laura, additional, Lodi, Alessandra, additional, Barreca, Filippo, additional, Crea, Angela, additional, Vitale, Pietro, additional, Spalliera, Ilaria, additional, Compagno, Mirko, additional, Coppola, Luigi, additional, Malagnino, Vincenzo, additional, Teti, Elisabetta, additional, Andreoni, Massimo, additional, Sarmati, Loredana, additional, and Marco, Iannetta, additional

Published
2022
Full Text
View/download PDF

15. 2071. HIV reservoir evaluation in GALT and PBMCs of virologically suppressed patients

Author

Compagno, Mirko, primary, Scutari, Rossana, additional, Ferrari, Ludovica, additional, Teti, Elisabetta, additional, Piermatteo, Lorenzo, additional, Matteucci, Claudia, additional, D’Avolio, Antonio, additional, Malagnino, Vincenzo, additional, Grelli, Sandri, additional, Marco, Iannetta, additional, Silberstein, Francesca Ceccherini, additional, Perri, Giovanni Di, additional, Sarmati, Loredana, additional, and Andreoni, Massimo, additional

Published
2022
Full Text
View/download PDF

16. Longitudinal Evaluation of the QuantiFERON-TB Gold Plus Assay in Hospitalized COVID-19 Patients with a First Indeterminate Result: Resolution of Inflammation and Restoration of T-Lymphocyte Counts and Interferon-Gamma Production

Author

Alessio, Grazia, primary, Imeneo, Alessandra, additional, Di Lorenzo, Andrea, additional, Rossi, Benedetta, additional, Sorace, Chiara, additional, Compagno, Mirko, additional, Coppola, Luigi, additional, Campogiani, Laura, additional, Crea, Angela Maria Antonia, additional, Malagnino, Vincenzo, additional, Buccisano, Francesco, additional, Andreoni, Massimo, additional, Sarmati, Loredana, additional, and Iannetta, Marco, additional

Published
2022
Full Text
View/download PDF

17. Hepatitis B–Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen–Positive Patient With HIV: Viroimmunological and Histological Characterization

Author

Iannetta, Marco, primary, Crea, Angela M A, additional, Di Lorenzo, Andrea, additional, Campogiani, Laura, additional, Teti, Elisabetta, additional, Malagnino, Vincenzo, additional, Compagno, Mirko, additional, Coppola, Luigi, additional, Piermatteo, Lorenzo, additional, Palmieri, Giampiero, additional, Cimino, Carolina, additional, Salpini, Romina, additional, Zingaropoli, Maria A, additional, Ciardi, Maria R, additional, Mastroianni, Claudio M, additional, Parisi, Saverio G, additional, Svicher, Valentina, additional, Andreoni, Massimo, additional, and Sarmati, Loredana, additional

Published
2022
Full Text
View/download PDF

18. Latent Tuberculosis Infection in Haematopoietic Stem Cell Transplant Recipients: A Retrospective Italian Cohort Study in Tor Vergata University Hospital, Rome

Author

Compagno, Mirko, primary, Navarra, Assunta, additional, Campogiani, Laura, additional, Coppola, Luigi, additional, Rossi, Benedetta, additional, Iannetta, Marco, additional, Malagnino, Vincenzo, additional, Parisi, Saverio G., additional, Mariotti, Benedetta, additional, Cerretti, Raffaella, additional, Arcese, William, additional, Goletti, Delia, additional, Andreoni, Massimo, additional, and Sarmati, Loredana, additional

Published
2022
Full Text
View/download PDF

19. Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine

Author

Ferrari, Ludovica, primary, Compagno, Mirko, additional, Campogiani, Laura, additional, Teti, Elisabetta, additional, Mulas, Tiziana, additional, Checchi, Davide, additional, Alessio, Grazia, additional, Caldara, Federica, additional, Coppola, Luigi, additional, De Simone, Giuseppe, additional, Ceccarelli, Laura, additional, Spalliera, Ilaria, additional, Vitale, Pietro, additional, Grelli, Sandro, additional, Andreoni, Massimo, additional, Sarmati, Loredana, additional, and Iannetta, Marco, additional

Published
2022
Full Text
View/download PDF

20. Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Author

Cusato, Jessica, Borghetti, Alberto, Teti, Elisabetta, Milesi, Maurizio, Tettoni, Maria Cristina, Bonora, Stefano, Trunfio, Mattia, D'Avolio, Antonio, Compagno, Mirko, Di Giambenedetto, Simona, Di Perri, Giovanni, Calcagno, Andrea, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Cusato, Jessica, Borghetti, Alberto, Teti, Elisabetta, Milesi, Maurizio, Tettoni, Maria Cristina, Bonora, Stefano, Trunfio, Mattia, D'Avolio, Antonio, Compagno, Mirko, Di Giambenedetto, Simona, Di Perri, Giovanni, Calcagno, Andrea, and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)

Abstract

Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir discontinuation was assessed and analyzed by real-time PCR. We enrolled 627 participants: CA/AA carriers showed a higher prevalence of pre-existing psychiatric comorbidities and use of antidepressants. After 27.9 months, 108 participants discontinued dolutegravir, 64 for neuropsychiatric symptoms. Patients with pre-existing psychiatric comorbidities were at higher risk of dolutegravir discontinuation, while patients carrying the SLC22A2 CA/AA genotype were not. Combining the two variables, an opposite effect of SLC22A2 variants according to pre-existing psychiatric disorders was observed. Using multivariate Cox models, the combined variable pre-existing psychiatric comorbidities/SLC22A2 variants and the use of non-tenofovir alafenamide containing antiretroviral regimens were predictors of dolutegravir discontinuation for neuropsychiatric symptoms. Within 30 days, the majority of participants had a complete resolution of symptoms (61.8%), while 32.7% and 5.5% had partial or no change after dolutegravir discontinuation, respectively. Discontinuation of dolutegravir for neuropsychiatric symptoms was not uncommon and more frequent in participants with pre-existing psychiatric disorders. We described an interaction between SLC22A2 genetic variant and psychiatric comorbidities. In 38.2% of patients, a complete neuropsychiatric symptoms resolution was not observed after dolutegravir discontinuation suggesting the involvement of additional factors.

Published
2022

21. Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020

Author

Lai, Alessia, Bergna, Annalisa, Toppo, Stefano, Morganti, Marina, Menzo, Stefano, Ghisetti, Valeria, Bruzzone, Bianca, Codeluppi, Mauro, Fiore, Vito, Rullo, Emmanuele Venanzi, Antonelli, Guido, Sarmati, Loredana, Brindicci, Gaetano, Callegaro, Annapaola, Sagnelli, Caterina, Francisci, Daniela, Vicenti, Ilaria, Miola, Arianna, Tonon, Giovanni, Cirillo, Daniela, Menozzi, Ilaria, Caucci, Sara, Cerutti, Francesco, Orsi, Andrea, Schiavo, Roberta, Babudieri, Sergio, Nunnari, Giuseppe, Mastroianni, Claudio M., Andreoni, Massimo, Monno, Laura, Guarneri, Davide, Coppola, Nicola, Crisanti, Andrea, Galli, Massimo, Zehender, Gianguglielmo, Balotta, Claudia, Ventura, Carla della, Schiuma, Marco, Lavezzo, Enrico, Fontana, Paolo, Bianco, Luca, Bertolotti, Luigi, Manuto, Laura, Grazioli, Marco, Bianca, Federico, Del Vecchio, Claudia, Franchin, Elisa, Onelia, Francesco, Spitaleri, Andrea, Saluzzo, Francesca, Lorenzin, Giovanni, Pongolini, Stefano, Scaltriti, Erika, Soliani, Laura, Bagnarelli, Patrizia, Turchi, Chiara, Onofri, Valerio, Melchionda, Filomena, Tagliabracci, Adriano, Burdino, Elisa, Milia, Maria Grazia, Caligiuri, Patrizia, De Pace, Vanessa, Ricucci, Valentina, Domnich, Alexander, Boccotti, Simona, Cristina, Leoni Maria, Cascio, Giuliana Lo, Rubino, Salvatore, Lai, Vincenzo, Rocca, Giulia, Govoni, Rosalba, Mancuso, Giuseppe, Campagna, Roberta, Mazzuti, Laura, Oliveto, Giuseppe, Turriziani, Ombretta, Campogiani, Laura, Compagno, Mirko, Coppola, Luigi, Crea, Angela Maria Antonia, De Simone, Giuseppe, Di Lorenzo, Andrea, Ferrari, Ludovica, Iannetta, Marco, Malagnino, Vincenzo, Mulas, Tiziana, Rossi, Benedetta, Spalliera, Ilaria, Tedde, Simona, Teti, Elisabetta, Vitale, Pietro, Zordan, Marta, Milano, Eugenio, Lagioia, Antonella, Gallitelli, Rosa, Starace, Mario, Minichini, Carmine, Di Fraia, Alessia, Schioppa, Maddalena, Greco, Rita, Gidari, Anna, Zazzi, Maurizio, Dragoni, Filippo, Puma, Laura Li, Ronchiadin, Silvia, Ruggerone, Luigi, Russignaga, Dario, Lai, Alessia, Bergna, Annalisa, Toppo, Stefano, Morganti, Marina, Menzo, Stefano, Ghisetti, Valeria, Bruzzone, Bianca, Codeluppi, Mauro, Fiore, Vito, Rullo, Emmanuele Venanzi, Antonelli, Guido, Sarmati, Loredana, Brindicci, Gaetano, Callegaro, Annapaola, Sagnelli, Caterina, Francisci, Daniela, Vicenti, Ilaria, Miola, Arianna, Tonon, Giovanni, Cirillo, Daniela, Menozzi, Ilaria, Caucci, Sara, Cerutti, Francesco, Orsi, Andrea, Schiavo, Roberta, Babudieri, Sergio, Nunnari, Giuseppe, Mastroianni, Claudio M, Andreoni, Massimo, Monno, Laura, Guarneri, Davide, Coppola, Nicola, Crisanti, Andrea, Galli, Massimo, and Zehender, Gianguglielmo

Subjects
Europe, Phylogeography, Genome, Italy, SARS-CoV-2, Communicable Disease Control, Humans, COVID-19, Genome, Viral, Viral, Settore MED/17, Human
Abstract

The aims of this study were to characterize new SARS-CoV-2 genomes sampled all over Italy and to reconstruct the origin and the evolutionary dynamics in Italy and Europe between February and June 2020. The cluster analysis showed only small clusters including < 80 Italian isolates, while most of the Italian strains were intermixed in the whole tree. Pure Italian clusters were observed mainly after the lockdown and distancing measures were adopted. Lineage B and B.1 spread between late January and early February 2020, from China to Veneto and Lombardy, respectively. Lineage B.1.1 (20B) most probably evolved within Italy and spread from central to south Italian regions, and to European countries. The lineage B.1.1.1 (20D) developed most probably in other European countries entering Italy only in the second half of March and remained localized in Piedmont until June 2020. In conclusion, within the limitations of phylogeographical reconstruction, the estimated ancestral scenario suggests an important role of China and Italy in the widespread diffusion of the D614G variant in Europe in the early phase of the pandemic and more dispersed exchanges involving several European countries from the second half of March 2020.

Published
2022

22. In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production

Author

Imeneo, Alessandra, primary, Alessio, Grazia, additional, Di Lorenzo, Andrea, additional, Campogiani, Laura, additional, Lodi, Alessandra, additional, Barreca, Filippo, additional, Zordan, Marta, additional, Barchi, Virginia, additional, Massa, Barbara, additional, Tedde, Simona, additional, Crea, Angela, additional, Vitale, Pietro, additional, Spalliera, Ilaria, additional, Compagno, Mirko, additional, Coppola, Luigi, additional, Dori, Luca, additional, Malagnino, Vincenzo, additional, Teti, Elisabetta, additional, Andreoni, Massimo, additional, Sarmati, Loredana, additional, and Iannetta, Marco, additional

Published
2022
Full Text
View/download PDF

23. Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study

Author

Tumbarello, Mario, Raffaelli, Francesca, Giannella, Maddalena, Mantengoli, Elisabetta, Mularoni, Alessandra, Venditti, Mario, De Rosa, Francesco Giuseppe, Sarmati, Loredana, Bassetti, Matteo, Brindicci, Gaetano, Rossi, Marianna, Luzzati, Roberto, Grossi, Paolo Antonio, Corona, Alberto, Capone, Alessandro, Falcone, Marco, Mussini, Cristina, Trecarichi, Enrico Maria, Cascio, Antonio, Guffanti, Elena, Russo, Alessandro, De Pascale, Gennaro, Tascini, Carlo, Gentile, Ivan, Losito, Angela Raffaella, Bussini, Linda, Conti, Giampaolo, Ceccarelli, Giancarlo, Corcione, Silvia, Compagno, Mirko, Giacobbe, Daniele Roberto, Saracino, Annalisa, Fantoni, Massimo, Antinori, Spinello, Peghin, Maddalena, Bonfanti, Paolo, Oliva, Alessandra, De Gasperi, Andrea, Tiseo, Giusy, Rovelli, Cristina, Meschiari, Marianna, Shbaklo, Nour, Spanu, Teresa, Cauda, Roberto, Viale, Pierluigi, Tumbarello, M, Raffaelli, F, Giannella, M, Mantengoli, E, Mularoni, A, Venditti, M, De Rosa, F, Sarmati, L, Bassetti, M, Brindicci, G, Rossi, M, Luzzati, R, Grossi, P, Corona, A, Capone, A, Falcone, M, Mussini, C, Trecarichi, E, Cascio, A, Guffanti, E, Russo, A, De Pascale, G, Tascini, C, Gentile, I, Losito, A, Bussini, L, Conti, G, Ceccarelli, G, Corcione, S, Compagno, M, Giacobbe, D, Saracino, A, Fantoni, M, Antinori, S, Peghin, M, Bonfanti, P, Oliva, A, De Gasperi, A, Tiseo, G, Rovelli, C, Meschiari, M, Shbaklo, N, Spanu, T, Cauda, R, and Viale, P

Subjects
Carbapenemase, carbapenemases, Ceftazidime-avibactam, ceftazidime-avibactam, KPC-producing Klebsiella pneumoniae
Abstract

Background: A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods: We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results: The cohort comprised 577 adults with bloodstream infections (n = 391) or nonbacteremic infections involving mainly the urinary tract, lower respiratory tract, and intra-abdominal structures. All received treatment with CAZ-AVI alone (n = 165) or with ≥1 other active antimicrobials (n = 412). The all-cause mortality rate 30 days after infection onset was 25% (146/577). There was no significant difference in mortality between patients managed with CAZ-AVI alone and those treated with combination regimens (26.1% vs 25.0%, P =. 79). In multivariate analysis, mortality was positively associated with presence at infection onset of septic shock (P =. 002), neutropenia (P

Published
2021

24. Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study

Author

Tumbarello, M, Raffaelli, F, Giannella, M, Mantengoli, E, Mularoni, A, Venditti, M, De Rosa, F, Sarmati, L, Bassetti, M, Brindicci, G, Rossi, M, Luzzati, R, Grossi, P, Corona, A, Capone, A, Falcone, M, Mussini, C, Trecarichi, E, Cascio, A, Guffanti, E, Russo, A, De Pascale, G, Tascini, C, Gentile, I, Losito, A, Bussini, L, Conti, G, Ceccarelli, G, Corcione, S, Compagno, M, Giacobbe, D, Saracino, A, Fantoni, M, Antinori, S, Peghin, M, Bonfanti, P, Oliva, A, De Gasperi, A, Tiseo, G, Rovelli, C, Meschiari, M, Shbaklo, N, Spanu, T, Cauda, R, Viale, P, Tumbarello, Mario, Raffaelli, Francesca, Giannella, Maddalena, Mantengoli, Elisabetta, Mularoni, Alessandra, Venditti, Mario, De Rosa, Francesco Giuseppe, Sarmati, Loredana, Bassetti, Matteo, Brindicci, Gaetano, Rossi, Marianna, Luzzati, Roberto, Grossi, Paolo Antonio, Corona, Alberto, Capone, Alessandro, Falcone, Marco, Mussini, Cristina, Trecarichi, Enrico Maria, Cascio, Antonio, Guffanti, Elena, Russo, Alessandro, De Pascale, Gennaro, Tascini, Carlo, Gentile, Ivan, Losito, Angela Raffaella, Bussini, Linda, Conti, Giampaolo, Ceccarelli, Giancarlo, Corcione, Silvia, Compagno, Mirko, Giacobbe, Daniele Roberto, Saracino, Annalisa, Fantoni, Massimo, Antinori, Spinello, Peghin, Maddalena, Bonfanti, Paolo, Oliva, Alessandra, De Gasperi, Andrea, Tiseo, Giusy, Rovelli, Cristina, Meschiari, Marianna, Shbaklo, Nour, Spanu, Teresa, Cauda, Roberto, Viale, Pierluigi, Tumbarello, M, Raffaelli, F, Giannella, M, Mantengoli, E, Mularoni, A, Venditti, M, De Rosa, F, Sarmati, L, Bassetti, M, Brindicci, G, Rossi, M, Luzzati, R, Grossi, P, Corona, A, Capone, A, Falcone, M, Mussini, C, Trecarichi, E, Cascio, A, Guffanti, E, Russo, A, De Pascale, G, Tascini, C, Gentile, I, Losito, A, Bussini, L, Conti, G, Ceccarelli, G, Corcione, S, Compagno, M, Giacobbe, D, Saracino, A, Fantoni, M, Antinori, S, Peghin, M, Bonfanti, P, Oliva, A, De Gasperi, A, Tiseo, G, Rovelli, C, Meschiari, M, Shbaklo, N, Spanu, T, Cauda, R, Viale, P, Tumbarello, Mario, Raffaelli, Francesca, Giannella, Maddalena, Mantengoli, Elisabetta, Mularoni, Alessandra, Venditti, Mario, De Rosa, Francesco Giuseppe, Sarmati, Loredana, Bassetti, Matteo, Brindicci, Gaetano, Rossi, Marianna, Luzzati, Roberto, Grossi, Paolo Antonio, Corona, Alberto, Capone, Alessandro, Falcone, Marco, Mussini, Cristina, Trecarichi, Enrico Maria, Cascio, Antonio, Guffanti, Elena, Russo, Alessandro, De Pascale, Gennaro, Tascini, Carlo, Gentile, Ivan, Losito, Angela Raffaella, Bussini, Linda, Conti, Giampaolo, Ceccarelli, Giancarlo, Corcione, Silvia, Compagno, Mirko, Giacobbe, Daniele Roberto, Saracino, Annalisa, Fantoni, Massimo, Antinori, Spinello, Peghin, Maddalena, Bonfanti, Paolo, Oliva, Alessandra, De Gasperi, Andrea, Tiseo, Giusy, Rovelli, Cristina, Meschiari, Marianna, Shbaklo, Nour, Spanu, Teresa, Cauda, Roberto, and Viale, Pierluigi

Abstract

Background: A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods: We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results: The cohort comprised 577 adults with bloodstream infections (n = 391) or nonbacteremic infections involving mainly the urinary tract, lower respiratory tract, and intra-abdominal structures. All received treatment with CAZ-AVI alone (n = 165) or with ≥1 other active antimicrobials (n = 412). The all-cause mortality rate 30 days after infection onset was 25% (146/577). There was no significant difference in mortality between patients managed with CAZ-AVI alone and those treated with combination regimens (26.1% vs 25.0%, P =. 79). In multivariate analysis, mortality was positively associated with presence at infection onset of septic shock (P =. 002), neutropenia (P <. 001), or an INCREMENT score ≥8 (P =. 01); with lower respiratory tract infection (LRTI) (P =. 04); and with CAZ-AVI dose adjustment for renal function (P =. 01). Mortality was negatively associated with CAZ-AVI administration by prolonged infusion (P =. 006). All associations remained significant after propensity score adjustment. Conclusions: CAZ-AVI is an important option for treating serious KPC-Kp infections, even when used alone. Further study is needed to explore the drug's seemingly more limited efficacy in LRTIs and potential survival benefits of prolonging CAZ-AVI infusions to ≥3 hours.

Published
2021

25. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study

Author

Tumbarello, Mario, primary, Raffaelli, Francesca, additional, Giannella, Maddalena, additional, Mantengoli, Elisabetta, additional, Mularoni, Alessandra, additional, Venditti, Mario, additional, De Rosa, Francesco Giuseppe, additional, Sarmati, Loredana, additional, Bassetti, Matteo, additional, Brindicci, Gaetano, additional, Rossi, Marianna, additional, Luzzati, Roberto, additional, Grossi, Paolo Antonio, additional, Corona, Alberto, additional, Capone, Alessandro, additional, Falcone, Marco, additional, Mussini, Cristina, additional, Trecarichi, Enrico Maria, additional, Cascio, Antonio, additional, Guffanti, Elena, additional, Russo, Alessandro, additional, De Pascale, Gennaro, additional, Tascini, Carlo, additional, Gentile, Ivan, additional, Losito, Angela Raffaella, additional, Bussini, Linda, additional, Corti, Giampaolo, additional, Ceccarelli, Giancarlo, additional, Corcione, Silvia, additional, Compagno, Mirko, additional, Giacobbe, Daniele Roberto, additional, Saracino, Annalisa, additional, Fantoni, Massimo, additional, Antinori, Spinello, additional, Peghin, Maddalena, additional, Bonfanti, Paolo, additional, Oliva, Alessandra, additional, De Gasperi, Andrea, additional, Tiseo, Giusy, additional, Rovelli, Cristina, additional, Meschiari, Marianna, additional, Shbaklo, Nour, additional, Spanu, Teresa, additional, Cauda, Roberto, additional, and Viale, Pierluigi, additional

Published
2021
Full Text
View/download PDF

26. HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort

Author

Malagnino, Vincenzo, primary, Teti, Elisabetta, additional, Compagno, Mirko, additional, Coppola, Luigi, additional, Salpini, Romina, additional, Svicher, Valentina, additional, Basso, Monica, additional, Battagin, Giuliana, additional, Panese, Sandro, additional, Rossi, Maria Cristina, additional, Scaggiante, Renzo, additional, Zago, Daniela, additional, Iannetta, Marco, additional, Parisi, Saverio Giuseppe, additional, Andreoni, Massimo, additional, and Sarmati, Loredana, additional

Published
2021
Full Text
View/download PDF

27. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

Author

Iannetta, Marco, primary, Cesta, Novella, additional, Stingone, Christof, additional, Malagnino, Vincenzo, additional, Teti, Elisabetta, additional, Vitale, Pietro, additional, De Simone, Giuseppe, additional, Rossi, Benedetta, additional, Ansaldo, Lorenzo, additional, Compagno, Mirko, additional, Spalliera, Ilaria, additional, Di Lorenzo, Andrea, additional, Landi, Doriana, additional, Nicoletti, Carolina Gabri, additional, Marfia, Girolama Alessandra, additional, Andreoni, Massimo, additional, and Sarmati, Loredana, additional

Published
2020
Full Text
View/download PDF

28. Tuberculosis-Related Hospitalizations in a Low-Incidence Country: A Retrospective Analysis in Two Italian Infectious Diseases Wards

Author

Campogiani, Laura, primary, Compagno, Mirko, additional, Coppola, Luigi, additional, Malagnino, Vincenzo, additional, Maffongelli, Gaetano, additional, Saraca, Lavinia Maria, additional, Francisci, Daniela, additional, Baldelli, Franco, additional, Fontana, Carla, additional, Grelli, Sandro, additional, Andreoni, Massimo, additional, Sotgiu, Giovanni, additional, Saderi, Laura, additional, and Sarmati, Loredana, additional

Published
2019
Full Text
View/download PDF

30. Inflammatory bowel disease versus Chlamydia trachomatisinfection: a case report and revision of the literature

Author

Neri, Benedetto, Stingone, Christof, Romeo, Samanta, Sena, Giorgia, Gesuale, Cristina, Compagno, Mirko, De Cristofaro, Elena, Baciorri, Francesca, Del Vecchio Blanco, Giovanna, Palmieri, Giampiero, Sarmati, Loredana, and Biancone, Livia

Abstract

Infectious proctitis may mimic inflammatory bowel disease, particularly when limited to the rectum. The present case report includes findings from a 50-year-old man, soldier, referring to our Inflammatory Bowel Disease Unit with a diagnosis of rectal Crohn’s disease, refractory to conventional treatments. Mild anemia, hypergammaglobulinemia and HIV-antibodies seronegativity were detected. Entero-MRI and stool examinations were negative. Ileocolonoscopy detected few rectal ulcers with irregular edges. Endosonography showed marked thickening of the rectal wall and enlarged perirectal lymphnodes. Nodal and rectal fine needle aspirate did not show atypia (PAN CK-). Rectal biopsies showed flogistic granular tissue (PAN CK-): Warthin-Starry stain was negative. Previous Treponema palliduminfection was detected. Clinical history revealed habits at risk for sexually transmitted infection. Rectal swabs for RT-PCR for Chlamydia trachomatis, Neisseria gonorrhoeae, and Herpes Simplex Virus 1-2lead to a diagnosis of lymphogranuloma venereum. Doxycycline 100 mg and Azitromicyn 500 mg t.i.d. were given for 21 days, followed by negativity for RT-PCR for Chlamydia trachomatisat rectal swabs. Complete disappearance of symptoms and mucosal healing occurred. Due to the increased frequency of infectious diseases, sexually transmitted infection (including lymphogranuloma venereum) should be considered as possible differential diagnosis when assessing patients with inflammatory bowel disease limited to the rectum.

Published
2020
Full Text
View/download PDF

32. Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

Author

Mirko Compagno, Giampaolo Corti, Maddalena Peghin, Francesca Raffaelli, Annalisa Saracino, Cristina Mussini, Spinello Antinori, Maddalena Giannella, Roberto Cauda, Marianna Rossi, Gennaro De Pascale, Elena Guffanti, Enrico Maria Trecarichi, Giancarlo Ceccarelli, Teresa Spanu, Elisabetta Mantengoli, Antonio Cascio, Mario Venditti, Loredana Sarmati, Carlo Tascini, Silvia Corcione, Daniele Roberto Giacobbe, Massimo Fantoni, Linda Bussini, Paolo Bonfanti, Alessandra Mularoni, Marianna Meschiari, Nour Shbaklo, Giusy Tiseo, Mario Tumbarello, Roberto Luzzati, Angela Raffaella Losito, Alessandra Oliva, Pierluigi Viale, Alessandro Russo, Francesco Giuseppe De Rosa, Gaetano Brindicci, Ivan Gentile, Alberto Corona, Andrea De Gasperi, Paolo Grossi, Marco Falcone, Alessandro Capone, Cristina Rovelli, Matteo Bassetti, Tumbarello M., Raffaelli F., Giannella M., Mantengoli E., Mularoni A., Venditti M., De Rosa F.G., Sarmati L., Bassetti M., Brindicci G., Rossi M., Luzzati R., Grossi P.A., Corona A., Capone A., Falcone M., Mussini C., Trecarichi E.M., Cascio A., Guffanti E., Russo A., De Pascale G., Tascini C., Gentile I., Losito A.R., Bussini L., Corti G., Ceccarelli G., Corcione S., Compagno M., Giacobbe D.R., Saracino A., Fantoni M., Antinori S., Peghin M., Bonfanti P., Oliva A., De Gasperi A., Tiseo G., Rovelli C., Meschiari M., Shbaklo N., Spanu T., Cauda R., Viale P., Tumbarello, Mario, Raffaelli, Francesca, Giannella, Maddalena, Mantengoli, Elisabetta, Mularoni, Alessandra, Venditti, Mario, De Rosa, Francesco Giuseppe, Sarmati, Loredana, Bassetti, Matteo, Brindicci, Gaetano, Rossi, Marianna, Luzzati, Roberto, Grossi, Paolo Antonio, Corona, Alberto, Capone, Alessandro, Falcone, Marco, Mussini, Cristina, Trecarichi, Enrico Maria, Cascio, Antonio, Guffanti, Elena, Russo, Alessandro, De Pascale, Gennaro, Tascini, Carlo, Gentile, Ivan, Losito, Angela Raffaella, Bussini, Linda, Conti, Giampaolo, Ceccarelli, Giancarlo, Corcione, Silvia, Compagno, Mirko, Giacobbe, Daniele Roberto, Saracino, Annalisa, Fantoni, Massimo, Antinori, Spinello, Peghin, Maddalena, Bonfanti, Paolo, Oliva, Alessandra, De Gasperi, Andrea, Tiseo, Giusy, Rovelli, Cristina, Meschiari, Marianna, Shbaklo, Nour, Spanu, Teresa, Cauda, Roberto, and Viale, Pierluigi

Subjects
Microbiology (medical), Adult, medicine.medical_specialty, Azabicyclo Compound, carbapenemases, Bacterial Protein, Microbial Sensitivity Tests, Neutropenia, Ceftazidime, beta-Lactamases, beta-Lactamase, Carbapenemase, carbapenemase, Bacterial Proteins, Retrospective Studie, Lower respiratory tract infection, Internal medicine, Drug Combination, Anti-Bacterial Agent, medicine, Humans, KPC-producing Klebsiella pneumoniae, Retrospective Studies, Septic shock, business.industry, Ceftazidime-avibactam, Microbial Sensitivity Test, ceftazidime-avibactam, Mortality rate, Carbapenemases, Anti-Bacterial Agents, Azabicyclo Compounds, Drug Combinations, Klebsiella Infections, Klebsiella pneumoniae, medicine.disease, Ceftazidime/avibactam, Settore MED/17, Infectious Diseases, Cohort, Propensity score matching, Observational study, business, medicine.drug, Human, Klebsiella Infection
Abstract

Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonbacteremic infections involving mainly the urinary tract, lower respiratory tract, and intra-abdominal structures. All received treatment with CAZ-AVI alone (n = 165) or with ≥1 other active antimicrobials (n = 412). The all-cause mortality rate 30 days after infection onset was 25% (146/577). There was no significant difference in mortality between patients managed with CAZ-AVI alone and those treated with combination regimens (26.1% vs 25.0%, P = .79). In multivariate analysis, mortality was positively associated with presence at infection onset of septic shock (P = .002), neutropenia (P < .001), or an INCREMENT score ≥8 (P = .01); with lower respiratory tract infection (LRTI) (P = .04); and with CAZ-AVI dose adjustment for renal function (P = .01). Mortality was negatively associated with CAZ-AVI administration by prolonged infusion (P = .006). All associations remained significant after propensity score adjustment. Conclusions CAZ-AVI is an important option for treating serious KPC-Kp infections, even when used alone. Further study is needed to explore the drug’s seemingly more limited efficacy in LRTIs and potential survival benefits of prolonging CAZ-AVI infusions to ≥3 hours.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results